Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) was featured on the latest episode of The BioMedWire Podcast, where co-founder and executive co-chair Anthony Durkacz discussed the company’s lead drug candidate, Lucid-MS, and its commercial alcohol metabolism product, unbuzzd™. The company is focused on advancing innovative therapies for neurodegenerative and metabolic disorders.
Durkacz highlighted that Lucid-MS is being developed to address mobility loss associated with multiple sclerosis by targeting nerve damage, an area he believes remains unmet by currently available treatments. The therapy aims to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, based on preclinical models. Quantum BioPharma is preparing for a Phase 2 clinical trial, which will be the first study to evaluate Lucid-MS in multiple sclerosis patients, following Phase 1 testing in healthy volunteers. This trial represents a critical step toward addressing a significant unmet need in the MS treatment landscape.
In addition to its pipeline, Durkacz discussed unbuzzd™, a commercial product designed to accelerate blood alcohol metabolism and currently available in the U.S. market. Quantum BioPharma retains a 19.84% ownership stake in Unbuzzd Wellness Inc. (as of March 31, 2026), the company that markets the OTC version of unbuzzd. The agreement includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses, providing a potential long-term revenue stream.
For business and technology leaders, the implications are twofold. First, the progression of Lucid-MS into Phase 2 trials signals potential advancement in treating multiple sclerosis, a disease affecting millions worldwide. If successful, Lucid-MS could disrupt the current MS therapy market by offering a novel mechanism targeting nerve damage and mobility loss. Second, the unbuzzd™ royalty structure provides Quantum BioPharma with a recurring revenue source without diluting focus on its core drug development. The 7% royalty until $250 million and 3% thereafter could generate substantial income if unbuzzd achieves widespread adoption, especially given the growing interest in health and wellness products.
The company’s dual focus on innovative drug development and commercial wellness products reflects a strategic approach to balancing high-risk pharmaceutical R&D with more immediate market opportunities. Investors and industry observers will likely watch the upcoming Phase 2 trial results closely, as they could validate Lucid-MS's potential and impact Quantum BioPharma's valuation. For more details, the full press release is available at https://ibn.fm/HURxt, and the latest news and updates relating to QNTM can be found in the company’s newsroom at https://ibn.fm/QNTM.
